Table 2. Evaluation of IC50.
| Hela | HCP4 | Ratio (Hela/HCP4) | PC3 | PCDP5 | Ratio (PC3/PCDP5) | |
|---|---|---|---|---|---|---|
| Lovastatin (μM) |
12.499 ±0.859 |
0.927 ±0.019 |
13.48 | 10.719 ±0.131 |
1.508 ±0.078 |
7.11 |
| Simvastatin (μM) |
1.961 ±0.958 |
0.111 ±0.007 |
17.67 | 1.052 ±0.147 |
0.216 ±0.098 |
4.87 |
| Compactin (μM) |
5.671 ±1.589 |
0.083 ±0.012 |
68.33 | 1.382 ±0.136 |
0.291 ±0.046 |
4.75 |
| Fluvastatin (μM) |
2.486 ±0.943 |
0.245 ±0.056 |
10.15 | 2.450 ±1.120 |
0.878 ±1.227 |
2.79 |
| Atorvastatin (μM) |
1.815 ±0.069 |
0.188 ±0.021 |
9.65 | 0.916 ±0.046 |
0.593 ±0.201 |
1.54 |
| Pitavastatin (μM) |
0.662 ±0.065 |
0.028 ±0.001 |
23.64 | 0.106 ±0.008 |
0.104 ±0.032 |
1.02 |
| Pravastatin (μM) |
>500 | 128.637 ±12.731 |
N.C. | >500 | >500 | N.C. |
N.C. indicates “not calculated”